title: Improvement of walking disturbance by beraprost sodium in rat femoral artery occlusion models.
abstract: In rats receiving bilateral femoral arteries ligation (day 0), repeated oral administration of the prostacyclin derivative beraprost sodium (50 microg/kg, b.i.d.) from day 1 to day 5 resulted in a significant prolongation in walking time in rotarod walking exercise performed on day 5. Similarly, results were obtained in rats with bilateral femoral arterial thrombosis induced by application of FeCl(3)/HCl. In the ligation model, a significant increase was observed in femoral/carotid arterial blood pressure ratio even on day 2. These results indicated that beraprost sodium improves blood flow and walking disturbances associated with arterial occlusion in rats.
authors.affiliation: Pharmaceutical Laboratories, Toray Industries, Inc., 1111 Tebiro, Kamakura, Kanagawa, 248-8555, Japan. Mitsuko_Miyamoto@nts.toray.co.jp
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Tayama
authors.forename: Sin'ichi
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kaneko
authors.forename: Hajimu
authors.initials: H
authors.lastname: Kurumatani
mesh_terms: D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005263:Femoral Artery; D007383:Intermittent Claudication / Q000188:drug therapy*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D016138:Walking
chemical_list: C048081:beraprost; D011464:Epoprostenol